期刊文献+

利奈唑胺致老年患者严重低血糖 乳酸酸中毒全血细胞减少一例并文献复习 被引量:5

Serious hypoglycemia,lactic acidosis and pancytopenia caused by Linezolid in elderly patients:a case report and literature review
原文传递
导出
摘要 目的分析并总结利奈唑胺引起老年患者低血糖、乳酸酸中毒、全血细胞减少严重不良反应的病例,旨在加强临床医生对利奈唑胺不良反应的认识。方法报道1例北京医院呼吸科收治的反复发作性尿路感染(RUTI)的患者,该患者在长疗程、反复使用利奈唑胺治疗过程中出现了严重低血糖、乳酸酸中毒、全血细胞减少的不良反应,同时收集2018年12月以前国内外报道的利奈唑胺引起以上3种严重、少见不良反应的文献,对利奈唑胺引起以上3种严重不良反应的危险因素、临床特点及预后情况进行总结分析。结果联同本例复习2018年12月以前应用利奈唑胺引起乳酸酸中毒、全血细胞减少、严重低血糖不良反应的病例共86例,86例患者男女比例为1.8∶1.0,中位年龄64.5岁,65岁及以上老年患者44例,占51.2%。发生乳酸酸中毒的57例患者合并肝脏、肾脏基础病疾病最多见,共25例(43.9%,25/57)。乳酸酸中毒不良反应发生时间为4 h^109 d,中位数值32 d,血乳酸峰值为2.6~38.1 mmol/L,中位数值13.3 mol/L。全血细胞减少不良反应发生于用药后4 h^120 d,中位数值21 d。低血糖不良反应发生时间为用药8 h^26 d,中位时间为10.3 d,血糖最低值为0.2 mmol/L。86例患者中61例(70.9%)患者好转,51例单纯发生乳酸酸中毒患者中有12例死亡,病死率为23.5%,单纯发生全血细胞减少和低血糖患者在及时停用利奈唑胺和对症治疗后病情均好转。结论临床医师在对老年患者应用利奈唑胺过程中应警惕低血糖、乳酸酸中毒、全血细胞减少的严重不良反应,建议在使用中注意监测血糖、血乳酸和血常规变化规律,避免长疗程使用利奈唑胺,使患者在最大程度上获益。 Objective To analyze and summarize adverse reactions such as hypoglycemia,lactic acidosis and pancytopenia caused by Linezolid in elderly patients,in order to enhance clinicians'awareness of adverse reactions of Linezolid.Methods One case with Linezolid-induced lactic acidosis,pancytopenia and hypoglycemia was reported in a patient receiving long-term and repeated use of Linezolid for recurrent urinary tract infections(RUTI)in Beijing Hospital.National and international literature on the three severe and rare adverse reactions caused by Linezolid before December 2018 was reviewed,and the risk factors,clinical characteristics and prognosis of the three severe adverse reactions caused by Linezolid were summarized and analyzed.Results A total of 86 cases with Linezolid-induced adverse reactions such as hypoglycemia,lactic acidosis and pancytopenia were analyzed.Among them,the ratio of males to females was 1.8∶1.0,the median age was 64.5 years,and 44 cases were over 65 years,accounting for 51.2%.Among the 57 patients with lactic acidosis,25 lactic acidosis cases were combined with liver and kidney diseases,which were the most commonly involved organs(43.9%,25/57).The time of onset for lactic acidosis was 4 h-109 d,with a median value of 32 d,and the peak values of blood lactate were 2.6-38.1 mmol/L,with a median value of 13.3 mol/L.Pancytopenia occurred 4 h-120 days after the treatment,and the median value was 21 days.The time of onset for hypoglycemia was 8 h-26,and the median time was 10.3 days.The lowest value of blood glucose was 0.2 mmol/L.Of the 86 cases,61(70.9%)patients improved,and 12 cases of 51 patients with lactic acidosis died,with a mortality rate of 23.5%.Conclusions Clinicians should be aware of serious adverse reactions including hypoglycemia,lactic acidosis and pancytopenia during Linezolid treatment in elderly patients.It is recommended to monitor changes in blood glucose,blood lactate and blood cell count during Linezolid treatment,and to avoid long-term use of Linezolid,so as to maximize the benefits for patients.
作者 王艳 仝亚琪 陈静 谭政 明树红 方保民 Wang Yan;Tong Yaqi;Chen Jing;Tan Zheng;Ming Shuhong;Fang Baomin(Department of Respiratory and Critical Care Medicine,Department of Health Care,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing 100730,China)
出处 《中华老年医学杂志》 CAS CSCD 北大核心 2020年第5期539-544,共6页 Chinese Journal of Geriatrics
基金 北京医院科技新星项目(BJ-2016-036) 国家自然科学基金项目(81300033)。
关键词 利奈唑胺 低血糖 全血细胞减少 酸中毒 乳酸性 Linezo1id Hypoglycemia Pancytopenia Acidosis lactic
  • 相关文献

参考文献9

二级参考文献89

  • 1朱浩翔,张永信.利奈唑胺治疗MRSA呼吸机相关性肺炎的评价[J].上海医药,2004,25(9):395-397. 被引量:6
  • 2周颖杰.利奈唑胺治疗严重感染建议在治疗复杂患者时监测不良反应[J].中国感染与化疗杂志,2006,6(5):345-345. 被引量:17
  • 3Bishop E, Melvani S, Howden BP, et al. Good clinical outcomes but high rates of adverse reactions during li- nezolid therapy for serious infections:a proposed protocol for monitoring therapy in complex patients [ J ]. Antimi- crob Agents Chemother, 2006, 50(4) :1599-1602.
  • 4Kohno S, Yamaguchi K, Aikawa N, et al. Linezolid ver- sus vancomycin for the treatment of infections caused bymethicillin-resistant Staphylococcus aureus in Japan[J]. J Antimicrob Chemother, 2007, 60 (6) : 1361-1369.
  • 5Grim SA, Rene L, Gupta S, et al. Safety of linezolid in patients with baseline thrombocytopenia [ J ]. J Antimicro Chemother, 2008, 62(4):850-851.
  • 6Gee T, Ellis R, Marshall G, et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses [ J ]. Antimicrob Agents Chermother, 2001, 45 (6) : 1843-1846.
  • 7Dalley CF, Pagano PJ, Buchanan LV, et al. Efficacy of linezolid plus rifamp in in an experimental model of methiciUin susceptible S taphylococcus aureus endocarditis [J ]. Antimicrob Agents Chemother, 2003, 47 ( 8 ) : 2655 -2658.
  • 8Garazzino S, De Rosa FG, Bargiacchi 0, et al. Haematological safety of long-term therapy with linezolid[ J]. Int J Antimicrob Agents, 2007, 29(4): 480483.
  • 9Gary French. Safety and tolerability of linezolid[ J]. Journal ofAntimicrobial Chemotherapy, 2003,51( Suppl) :45-53.
  • 10Zhang QL, Rothenbacher D. Prevalence of chronic kidney dis-ease in population-based studies: Systematic review[ J]. BMCPublic Health,2008,8:117.

共引文献35

同被引文献46

引证文献5

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部